PRESS RELEASES

Date Title View
Toggle Summary Chimerix Announces First Quarter 2019 Financial Results and Strategy Update
– Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission – – Plan to Focus on Execution of Smallpox Program, Halting All Other Brincidofovir Development Activities – – Restructuring to Reduce Workforce by More Than 50%,
View HTML
Toggle Summary Chimerix to Announce First Quarter 2019 Financial Results on May 9, 2019
DURHAM, N.C. , May 02, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Thursday, May 9, 2019 at 8:30 a.m.
View HTML
Toggle Summary Chimerix Announces Management Updates
Mike Sherman Appointed Chief Executive Officer and Mike Andriole Appointed Chief Business Officer DURHAM, N.C. , April 08, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announces the appointment of
View HTML
Toggle Summary Chimerix Announces Fourth Quarter and Full Year 2018 Financial Results
– Reports Positive Preliminary Top-line Data from Second Rabbitpox Study – – Type C Meeting Requested with FDA Regarding Virologic Endpoint – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , March 05, 2019 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing
View HTML
Toggle Summary Chimerix to Present at Cowen and Company 39th Annual Health Care Conference
DURHAM, N.C. , March 04, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that Timothy Trost , Chief Financial Officer of Chimerix, will present at the Cowen and Company 39th Annual
View HTML
Toggle Summary Chimerix to Announce Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019
DURHAM, N.C. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Tuesday, March 5, 2019 at 8:30 a.m.
View HTML
Toggle Summary Chimerix Presents Results from Post-hoc Analysis of Phase 3 Study
Decreased HHV-6 Reactivation Observed Among Oral Brincidofovir Allogeneic Hematopoietic Cell Transplantation Recipients Results to be Presented at Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR 2019 DURHAM, N.C. , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a
View HTML
Toggle Summary Chimerix Announces Management Transition
M. Michelle Berrey to Step Down as Chief Executive Officer DURHAM, N.C. , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M.
View HTML
Toggle Summary Chimerix to Present at the 37th Annual J.P. Morgan Healthcare Conference
DURHAM, N.C. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at
View HTML
Toggle Summary Chimerix Announces Third Quarter 2018 Financial Results
- Conference Call at 8:30 a.m. ET Today - DURHAM, N.C. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today reported financial results and provided a corporate update for the third
View HTML